62996-74-1 Usage
Description
Staurosporine (Stsp) is potent inhibitor of protein kinase C (PKC) from rat brain, exhibiting an IC50 value of 2.7 nM. It inhibits rat recombinant PKC-α approximately 100- and 1,000-fold better than PKC-δ and PKC-ζ, respectively. However, Stsp is non-selective in that it also inhibits the activity of a variety of other protein kinases, not only PKC isoforms. The biological effects of Stsp include cytotoxicity, relaxation of smooth muscle, and regulation of eNOS gene expression.
Chemical Properties
Light Yellow Solid
Occurrence
A complex alkaloid. staurosporine has been isolated from a strain of Streptomyces.
Uses
Different sources of media describe the Uses of 62996-74-1 differently. You can refer to the following data:
1. Staurosporine is a protein Kinase C inhibitor that induces apoptosis in many cell types.
2. A protein Kinase C inhibitor that induces apoptosis in many cell types
3. Staurosporine is an unusual indolocarbazole alkaloid produced by a range of actinomycete species. It is a potent antitumour active, inducing apoptosis in a variety of cell lines. Staurosporine is a potent inhibitor of many kinases including protein kinase C, tyrosine kinase, CDK2/cyclin A and CDK4/cyclin D. At submicromolar concentrations, staurosporine inhibits both IKKalpha and IKKbeta.
General Description
A potent, cell-permeable, reversible, ATP-competitive and broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.
Biological Activity
Broad spectrum protein kinase inhibitor. Enzymes inhibited include protein kinase C (IC 50 = 3 nM), protein kinase A (IC 50 = 7 nM), p 60v-src tyrosine protein kinase (IC 50 = 6 nM) and CaM kinase II (IC 50 = 20 nM). Also available as part of the Mixed Kinase Inhibitor Tocriset? .
References
1) Omura et al. (1977) A new alkaloid AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization; J. Antibiot., 30 275
2) Ruegg and Burgess (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases; Trends in Pharmacological Science 10 218
Check Digit Verification of cas no
The CAS Registry Mumber 62996-74-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,9,9 and 6 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 62996-74:
(7*6)+(6*2)+(5*9)+(4*9)+(3*6)+(2*7)+(1*4)=171
171 % 10 = 1
So 62996-74-1 is a valid CAS Registry Number.
InChI:InChI=1/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/p+1/t17-,20-,26-,28+/m1/s1
62996-74-1Relevant articles and documents
PROCESS FOR THE PURIFICATION OF INDOLE CARBAZOLE ALKALOIDS
-
Page/Page column 16, (2021/09/11)
Disclosed is a process for the purification of staurosporine (1), which comprises salification of staurosporine (1) (Formula (1)) by treatment with a mineral acid to give a precipitated salt, isolation of the staurosporine (1) precipitated salt, treatment of the staurosporine (1) isolated salt with an organic base, and isolation of staurosporine (1). Also disclosed are novel polymorphic forms of the mono- and bis-hydrochloride salts of staurosporine (1).
Design and implementation of an efficient synthetic approach to pyranosylated indolocarbazoles: Total synthesis of (+)-RK286c, (+)-MLR-52, (+)-staurosporine, and (-)-TAN-1030a
Wood, John L.,Stoltz, Brian M.,Goodman, Steven N.,Onwueme, Kenolisa
, p. 9652 - 9661 (2007/10/03)
A total synthesis of the natural products (+)-staurosporine (2), (+)-RK286c (3), (-)-TAN-1030a (4), and (+)-MLR-52 (5) has been achieved. The synthetic strategy involves the stereoselective ring expansion of a furanosylated indolocarbazole [(+)-8] to a pyranosylated congener [(+)-12] that serves as a common intermediate in the production of 2-5.
Staurosporine and ent-staurosporine: The first total syntheses, prospects for a regioselective approach, and activity profiles
Link,Raghavan, Subharekha,Gallant, Michel,Danishefsky, Samuel J.,Chou,Ballas, Lawrence M.
, p. 2825 - 2842 (2007/10/03)
The total syntheses of staurosporine and ent-staurosporine have been achieved. Both glycosidic bonds were built from glycal precursors. The first was constructed by intermolecular coupling of an indole anion with a 1,2-anhydrosugar derived from an endo-glycal by direct epoxidation. The second bond was assembled from an exo-glycal by intramolecular iodoglycosylation.
